2-phenylpiperidine hydrochloride | 3466-81-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-phenylpiperidine hydrochloride
• 英文别名: 2-phenylpiperidine;hydrochloride
• CAS: 3466-81-7
• 化学式: C₁₁H₁₅N*ClH
• mdl: MFCD02179093
• 分子量: 197.708
• InChiKey: YNQTWZUWWFUKSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.44
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (Z)-4-(3-carbamoylphenylamino)-4-oxobut-2-enoic acid 、 2-phenylpiperidine hydrochloride 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以10%的产率得到MCD-76
  参考文献：
  名称：

  单（ADP-核糖基）转移酶PARP14的有效抑制剂的设计与合成

  摘要：

  合成了一系列（Z）-4-（3-氨基甲酰基苯基氨基）-4-氧代丁-2-烯基酰胺，并测试了它们抑制单-（ADP-核糖基）转移酶PARP14（aka BAL-2; ARTD）的能力。 -8）。针对该系列建立了两种合成途径，已鉴定出几种化合物为PARP14的亚微摩尔抑制剂，其中最有效的是化合物4t，IC 50  = 160 nM。此外，对该系列的其他成员进行了分析，鉴定出的化合物的选择性是PARP5a / TNKS1的20倍以上，而PARP10是密切相关的单-（ADP-核糖基）转移酶。

  DOI：

  10.1016/j.bmcl.2017.04.089
• 作为产物：
  描述：

  1-Boc-哌啶 在 盐酸 、 四甲基乙二胺 、 仲丁基锂 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 23.0h， 生成 2-phenylpiperidine hydrochloride
  参考文献：
  名称：

  A novel inhibitor of inducible NOS dimerization protects against cytokine-induced rat beta cell dysfunction

  摘要：

  Background and PurposeBeta cell apoptosis is a major feature of type 1 diabetes, and pro‐inflammatory cytokines are key drivers of the deterioration of beta cell mass through induction of apoptosis. Mitochondrial stress plays a critical role in mediating apoptosis by releasing cytochrome C into the cytoplasm, directly activating caspase‐9 and its downstream signalling cascade. We aimed to identify new compounds that protect beta cells from cytokine‐induced activation of the intrinsic (mitochondrial) pathway of apoptosis.Experimental ApproachDiabetogenic media, composed of IL‐1β, IFN‐γ and high glucose, were used to induce mitochondrial stress in rat insulin‐producing INS1E cells, and a high‐content image‐based screen of small molecule modulators of Casp9 pathway was performed.Key ResultsA novel small molecule, ATV399, was identified from a high‐content image‐based screen for compounds that inhibit cleaved caspase‐9 activation and subsequent beta cell apoptosis induced by a combination of IL‐1β, IFN‐γ and high glucose, which together mimic the pathogenic diabetic milieu. Through medicinal chemistry optimization, potency was markedly improved (6–30 fold), with reduced inhibitory effects on CYP3A4. Improved analogues, such as CAT639, improved beta cell viability and insulin secretion in cytokine‐treated rat insulin‐producing INS1E cells and primary dispersed islet cells. Mechanistically, CAT639 reduced the production of NO by allosterically inhibiting dimerization of inducible NOS (iNOS) without affecting its mRNA levels.Conclusion and ImplicationsTaken together, these studies demonstrate a successful phenotypic screening campaign resulting in identification of an inhibitor of iNOS dimerization that protects beta cell viability and function through modulation of mitochondrial stress induced by cytokines.

  DOI：

  10.1111/bph.14388

文献信息

• SULTAM DERIVATIVES
  申请人：Anderson Kevin W.

  公开号：US20110124686A1

  公开（公告）日：2011-05-26

  The present invention relates to compounds according to formula 1, which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.

  本发明涉及符合式1的化合物，具有细胞毒活性。这些化合物可用于治疗癌症。
• [EN] THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2017058821A1

  公开（公告）日：2017-04-06

  The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  这项发明提供了一个化合物的结构式：或其盐，其中变量RAA、n、环A、环B、R1a、R1b、R2、R3、R4、R5、R6、R7、R8和R9的含义如本文所述，并包含这种化合物的组合物以及使用这种化合物和组合物的方法。
• [EN] STEREOSELECTIVE PREPARATION OF SUBSTITUTED PIPERIDINES
  申请人：PFIZER INC.

  公开号：WO1992017449A1

  公开（公告）日：1992-10-15

  (EN) Novel processes are disclosed for the stereoselective preparation of substituted piperidine derivatives of formulae (IV) and (I) wherein R1 and R2 are defined as below.(FR) Nouveaux procédés de préparation stéréosélective de dérivés de pipéridine substituée répondant aux formules (IV) et (I), dans lesquelles R1 et R2 ont les mêmes notations que ci-dessous.

  (中文) 揭示了用于立体选择性制备式（IV）和（I）的取代哌啶衍生物的新工艺，其中R1和R2如下所定义。
• Diaryl ethers as opioid receptor antagonist
  申请人：Blanco-Pillado Maria-Jesus

  公开号：US20060217372A1

  公开（公告）日：2006-09-28

  A compound of the formula (I) wherein the variables X 1 to X 10 , R 1 to R 7 including R 3′ , E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

  本发明公开了一种化合物（I）的公式，其中变量X1至X10，R1至R7包括R3'，E，v，y，z，A和B如所述，或其药学上可接受的盐，溶剂合物，对映体，外消旋体，非对映体异构体或其混合物，用于治疗、预防或缓解肥胖和相关疾病。
• DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
  申请人：Blanco-Pillado Maria-Jesus

  公开号：US20080255152A1

  公开（公告）日：2008-10-16

  A compound of the formula (I) wherein the variables X 1 to X 10 , R 1 to R 7 including R 3′ , E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

  本发明揭示了一种式(I)的化合物，其中变量X1至X10，R1至R7包括R3′，E，v，y，z，A和B如所述，或其药学上可接受的盐，溶剂合物，对映体，外消旋体，非对映体异构体或其混合物，用于治疗、预防或改善肥胖和相关疾病。